CN108135882A - 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 - Google Patents
包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 Download PDFInfo
- Publication number
- CN108135882A CN108135882A CN201680058043.2A CN201680058043A CN108135882A CN 108135882 A CN108135882 A CN 108135882A CN 201680058043 A CN201680058043 A CN 201680058043A CN 108135882 A CN108135882 A CN 108135882A
- Authority
- CN
- China
- Prior art keywords
- perindopril
- atorvastatin
- aspirin
- pharmaceutical
- drug composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1570030 | 2015-08-27 | ||
FR1570030A FR3040303B1 (fr) | 2015-08-27 | 2015-08-27 | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
PCT/FR2016/052126 WO2017032953A1 (fr) | 2015-08-27 | 2016-08-26 | COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE LA HMG-CoA REDUCTASE ET UN INHIBITEUR ECA |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108135882A true CN108135882A (zh) | 2018-06-08 |
Family
ID=54708062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680058043.2A Pending CN108135882A (zh) | 2015-08-27 | 2016-08-26 | 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3340980A1 (ko) |
KR (1) | KR20180041233A (ko) |
CN (1) | CN108135882A (ko) |
BR (1) | BR112018003392A2 (ko) |
EA (1) | EA038261B1 (ko) |
FR (1) | FR3040303B1 (ko) |
GE (1) | GEP20207170B (ko) |
MA (1) | MA42696A (ko) |
MX (1) | MX2018002373A (ko) |
PH (1) | PH12018500370A1 (ko) |
RU (1) | RU2750934C2 (ko) |
SG (2) | SG10202000597UA (ko) |
TN (1) | TN2018000055A1 (ko) |
UA (1) | UA122908C2 (ko) |
WO (1) | WO2017032953A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102245273B1 (ko) * | 2019-03-15 | 2021-04-28 | 서울대학교병원 | 노르안하이드로이카리틴을 포함하는 심혈관 대사 질환의 예방 또는 치료용 조성물 |
EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011260A1 (en) * | 1997-08-29 | 1999-03-11 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
WO2004080488A2 (de) * | 2003-03-10 | 2004-09-23 | Bayer Healthcare Ag | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase |
WO2009093264A2 (en) * | 2008-01-25 | 2009-07-30 | Torrent Pharmaceuticals Ltd. | Pharmaceutical combinations |
CN101612403A (zh) * | 2009-08-13 | 2009-12-30 | 王丽燕 | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 |
CN101791297A (zh) * | 2010-02-10 | 2010-08-04 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
FR2838648B1 (fr) * | 2002-04-18 | 2004-05-21 | Servier Lab | Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent |
SI2120878T1 (sl) * | 2007-02-09 | 2014-12-31 | Alphapharm Pty Ltd | Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah |
-
2015
- 2015-08-27 FR FR1570030A patent/FR3040303B1/fr not_active Expired - Fee Related
-
2016
- 2016-08-26 WO PCT/FR2016/052126 patent/WO2017032953A1/fr active Application Filing
- 2016-08-26 SG SG10202000597UA patent/SG10202000597UA/en unknown
- 2016-08-26 MX MX2018002373A patent/MX2018002373A/es unknown
- 2016-08-26 EA EA201890591A patent/EA038261B1/ru unknown
- 2016-08-26 KR KR1020187008533A patent/KR20180041233A/ko not_active Application Discontinuation
- 2016-08-26 TN TNP/2018/000055A patent/TN2018000055A1/en unknown
- 2016-08-26 UA UAA201802860A patent/UA122908C2/uk unknown
- 2016-08-26 RU RU2018110622A patent/RU2750934C2/ru active
- 2016-08-26 BR BR112018003392-8A patent/BR112018003392A2/pt not_active IP Right Cessation
- 2016-08-26 CN CN201680058043.2A patent/CN108135882A/zh active Pending
- 2016-08-26 SG SG11201801382UA patent/SG11201801382UA/en unknown
- 2016-08-26 GE GEAP201614734A patent/GEP20207170B/en unknown
- 2016-08-26 MA MA042696A patent/MA42696A/fr unknown
- 2016-08-26 EP EP16763927.7A patent/EP3340980A1/fr not_active Withdrawn
-
2018
- 2018-02-19 PH PH12018500370A patent/PH12018500370A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011260A1 (en) * | 1997-08-29 | 1999-03-11 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
WO2004080488A2 (de) * | 2003-03-10 | 2004-09-23 | Bayer Healthcare Ag | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase |
WO2009093264A2 (en) * | 2008-01-25 | 2009-07-30 | Torrent Pharmaceuticals Ltd. | Pharmaceutical combinations |
CN101612403A (zh) * | 2009-08-13 | 2009-12-30 | 王丽燕 | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 |
CN101791297A (zh) * | 2010-02-10 | 2010-08-04 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
欧洲药品管理局: "EMEA-001547-PIP01-13", 《EUROPEAN MEDICINES AGENCY DECISION》 * |
Also Published As
Publication number | Publication date |
---|---|
FR3040303A1 (fr) | 2017-03-03 |
BR112018003392A2 (pt) | 2018-09-25 |
UA122908C2 (uk) | 2021-01-20 |
RU2018110622A (ru) | 2019-09-27 |
EA038261B1 (ru) | 2021-07-30 |
MX2018002373A (es) | 2018-07-06 |
WO2017032953A1 (fr) | 2017-03-02 |
PH12018500370A1 (en) | 2018-08-29 |
TN2018000055A1 (en) | 2019-07-08 |
EP3340980A1 (fr) | 2018-07-04 |
MA42696A (fr) | 2018-07-04 |
GEP20207170B (en) | 2020-10-12 |
FR3040303B1 (fr) | 2019-04-05 |
SG10202000597UA (en) | 2020-03-30 |
RU2018110622A3 (ko) | 2020-01-31 |
SG11201801382UA (en) | 2018-03-28 |
EA201890591A1 (ru) | 2018-09-28 |
KR20180041233A (ko) | 2018-04-23 |
RU2750934C2 (ru) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5377317B2 (ja) | 放出性が制御されたアンジオテンシン−II−受容体遮断剤とHMG−CoA還元酵素阻害剤の複合組成物 | |
AU2007288544B2 (en) | Combined pharmaceutical formulation with controlled-release comprising Dihydropyridine calcium channel blockers and HMG-CoA reductase inhibitors | |
US20070087048A1 (en) | Oral dosage combination pharmaceutical packaging | |
KR20090017423A (ko) | HMGCoA 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법 | |
CN101980701A (zh) | 用于预防心血管疾病的胶囊 | |
JP2009511191A (ja) | 経口投与剤組合せ型医薬パッケージ法 | |
CN101658675A (zh) | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 | |
CN105120845A (zh) | 药物组合药物 | |
CN108135882A (zh) | 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 | |
CN104602678A (zh) | 包含厄贝沙坦和hmg-coa还原酶抑制剂的药物复合胶囊制剂 | |
CN104127391B (zh) | 一种含有阿托伐他汀钙的固体药物组合物 | |
KR20150072367A (ko) | HMG-CoA 리덕타제 억제제 및 콜레스테롤 흡수 억제제를 포함하는 약제학적 복합제제 | |
CN103239725A (zh) | 一种治疗心脑血管疾病复方制剂 | |
ES2387913T3 (es) | Preparaciones de combinación de sales del ácido O-acetilsalicílico | |
US20080241240A1 (en) | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors | |
EP1741431B1 (en) | The combination for treating hyperlipemia | |
US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
WO2004080488A2 (de) | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase | |
CN101985041A (zh) | 含有氯吡格雷和他汀类化合物的药物组合物 | |
CN100566716C (zh) | 治疗高血脂症的组合物 | |
KR102267965B1 (ko) | 베타 차단제, 전환 효소 억제제 및 항고혈압제 또는 nsaid를 포함하는 약학적 조성물 | |
CN101357132B (zh) | 治疗高血脂症的组合物 | |
JPH1081633A (ja) | 医薬組成物 | |
CN106955355A (zh) | 他汀类药物与蚓激酶的药物组合物、制剂及其应用 | |
MX2008004895A (en) | Pharmaceutical packaging of an oral dosage combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180608 |
|
RJ01 | Rejection of invention patent application after publication |